BioXcel Financial Statements (BTAI)
|
|
|
|
Report date
|
|
|
11.03.2022 |
16.03.2023 |
22.03.2024 |
28.03.2025 |
27.03.2026 |
|
15.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
0.000 |
0.375 |
1.38 |
2.27 |
0.642 |
|
0.680 |
|
Operating Income, bln rub |
|
|
-106.9 |
-159.6 |
-171.8 |
-67.2 |
-50.3 |
|
-50.3 |
|
EBITDA, bln rub |
? |
|
-106.6 |
-157.2 |
-165.4 |
-44.2 |
-52.6 |
|
-59.5 |
|
Net profit, bln rub |
? |
|
-106.9 |
-165.8 |
-179.1 |
-59.6 |
-69.9 |
|
-75.3 |
|
|
OCF, bln rub |
? |
|
-82.2 |
-135.3 |
-155.0 |
-72.0 |
-57.6 |
|
-57.4 |
|
CAPEX, bln rub |
? |
|
0.445 |
0.139 |
0.020 |
0.000 |
0.000 |
|
0.000 |
|
FCF, bln rub |
? |
|
-82.6 |
-135.5 |
-155.0 |
-72.0 |
-57.6 |
|
-57.4 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
|
|
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
106.9 |
160.0 |
171.9 |
67.4 |
50.7 |
|
50.5 |
|
Cost of production, bln rub |
|
|
0.000 |
0.020 |
1.26 |
2.14 |
0.164 |
|
0.491 |
|
R&D, bln rub |
|
|
52.7 |
91.2 |
84.3 |
30.4 |
30.3 |
|
28.7 |
|
Interest expenses, bln rub |
|
|
0.040 |
8.21 |
13.3 |
15.1 |
17.0 |
|
17.2 |
|
|
Assets, bln rub |
|
|
239.4 |
205.9 |
73.7 |
38.3 |
44.9 |
|
34.0 |
|
Net Assets, bln rub |
? |
|
221.7 |
76.8 |
-56.5 |
-93.1 |
-95.5 |
|
-105.5 |
|
Debt, bln rub |
|
|
1.40 |
94.2 |
101.4 |
102.9 |
109.7 |
|
100.3 |
|
Cash, bln rub |
|
|
233.0 |
193.7 |
65.2 |
29.9 |
28.4 |
|
17.2 |
|
Net debt, bln rub |
|
|
-231.6 |
-99.6 |
36.2 |
73.1 |
81.2 |
|
83.1 |
|
|
Ordinary share price, rub |
|
|
325.3 |
|
|
5.98 |
1.60 |
|
1.20 |
|
Number of ordinary shares, mln |
|
|
1.65 |
1.75 |
1.82 |
2.54 |
12.2 |
|
12.2 |
|
|
Market cap, bln rub |
|
|
536 |
0 |
0 |
15 |
20 |
|
15 |
|
EV, bln rub |
? |
|
305 |
-100 |
36 |
88 |
101 |
|
98 |
|
Book value, bln rub |
|
|
222 |
77 |
-57 |
-93 |
-95 |
|
-106 |
|
|
EPS, rub |
? |
|
-64.9 |
-94.7 |
-98.4 |
-23.5 |
-5.73 |
|
-6.17 |
|
FCF/share, rub |
|
|
-50.1 |
-77.4 |
-85.2 |
-28.4 |
-4.72 |
|
-4.70 |
|
BV/share, rub |
|
|
134.5 |
43.8 |
-31.0 |
-36.7 |
-7.82 |
|
-8.65 |
|
|
EBITDA margin, % |
? |
|
|
-41 925% |
-11 987% |
-1 949% |
-8 195% |
|
-8 748% |
|
Net margin, % |
? |
|
|
-44 202% |
-12 975% |
-2 630% |
-10 887% |
|
-11 079% |
|
FCF yield, % |
? |
|
-15.4% |
|
|
-475.1% |
-295.0% |
|
-391.7% |
|
ROE, % |
? |
|
-48.2% |
-215.9% |
316.9% |
64.0% |
73.2% |
|
71.4% |
|
ROA, % |
? |
|
-44.7% |
-80.5% |
-242.9% |
-155.5% |
-155.6% |
|
-221.4% |
|
|
P/E |
? |
|
-5.01 |
0.00 |
0.00 |
-0.25 |
-0.28 |
|
-0.19 |
|
P/FCF |
|
|
-6.49 |
0.00 |
0.00 |
-0.21 |
-0.34 |
|
-0.26 |
|
P/S |
? |
|
|
0.00 |
0.00 |
6.69 |
30.4 |
|
21.5 |
|
P/BV |
? |
|
2.42 |
0.00 |
0.00 |
-0.16 |
-0.20 |
|
-0.14 |
|
EV/EBITDA |
? |
|
-2.86 |
0.63 |
-0.22 |
-2.00 |
-1.92 |
|
-1.64 |
|
Debt/EBITDA |
|
|
2.17 |
0.63 |
-0.22 |
-1.66 |
-1.54 |
|
-1.40 |
|
|
R&D/CAPEX, % |
|
|
11 844% |
65 640% |
421 630% |
|
|
|
|
|
|
CAPEX/Revenue, % |
|
|
|
37.1% |
1.45% |
0.00% |
0.00% |
|
0 |
|
| BioXcel shareholders |
